LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Închisă

SectorSănătate

13.24 1.46

Rezumat

Modificarea prețului

24h

Curent

Minim

13.02

Maxim

13.33

Indicatori cheie

By Trading Economics

Venit

-9.7B

2.2B

Vânzări

-11B

76B

P/E

Medie Sector

24.556

49.888

Randament dividend

0.63

Marjă de profit

2.928

Angajați

27,527

EBITDA

-13B

6.1B

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.63%

2.38%

Statistici piață

By TradingEconomics

Capitalizare de piață

68M

11B

Deschiderea anterioară

11.78

Închiderea anterioară

13.24

Sentimentul știrilor

By Acuity

50%

50%

155 / 344 Clasament în Healthcare

Dr Reddy's Laboratories Ltd-ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 oct. 2025, 14:47 UTC

Principalele dinamici ale pieței

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12 mai 2026, 12:16 UTC

Câștiguri

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12 mai 2026, 12:16 UTC

Câștiguri

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12 mai 2026, 12:08 UTC

Câștiguri

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12 mai 2026, 12:06 UTC

Câștiguri

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12 mai 2026, 12:02 UTC

Câștiguri

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12 mai 2026, 12:01 UTC

Câștiguri

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23 iul. 2025, 17:49 UTC

Câștiguri

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 iul. 2025, 17:48 UTC

Câștiguri

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 iul. 2025, 17:48 UTC

Câștiguri

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Comparație

Modificare preț

Dr Reddy's Laboratories Ltd-ADR Așteptări

Consens privind evaluarea

By TipRanks

Vânzare

1 ratings

0

Cumpărare

0

Păstrare

1

Vânzare

Sentiment

By Acuity

155 / 344 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat